There are currently 240 clinical trials in Hartford, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Hartford Hospital, Connecticut Children's Medical Center, Smilow Cancer Hospital Care Center at Saint Francis and Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Hartford HealthCare Cancer Institute at Hartford Hospital, Hartford, Connecticut
Conditions: Endometrial Cancer
Register for Updates
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
NCT05260047
Recruiting
The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Blackwell Memorial AME Church, Hartford, Connecticut +1 locations
Conditions: Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
Register for Updates
STOP Persistent AF PAS
NCT05005949
Recruiting
The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Persistent Atrial Fibrillation
Register for Updates
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/18/2025
Locations: Hartford Hospital (site 210), Hartford, Connecticut
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
06/18/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Register for Updates
A Study on the Effects of Exercise on Side Effects From Treatment for Gastrointestinal Cancers
NCT05789485
Recruiting
The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Hartford Healthcare Alliance (Data Collection Only), Hartford, Connecticut
Conditions: Gastrointestinal Cancer
Register for Updates
Evolutionary Therapy for Rhabdomyosarcoma
NCT04388839
Recruiting
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma. The participant and their physician will choose from: Arm A) a first strike therapy, Arm B) a first strike-second strike (maintenance) therapy, Arm C) an adaptively timed therapy, and Arm D) conventional chemotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
06/16/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Rhabdomyosarcoma
Register for Updates
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Ischemic Stroke
Register for Updates
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
NCT05203965
Recruiting
The purpose of this study is to evaluate the role of Mavoglurant in clarifying the neurobiology of alcoholism risk. This is a one-site, randomized, within subjects, counterbalanced double-blind study of a single dose (200mg) of Mavoglurant and placebo.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/16/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Familial Alcoholism Vulnerability
Register for Updates
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
NCT05865535
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cachexia
Register for Updates
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
NCT03847467
Recruiting
Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and well tolerated, while increasing fecal Bifidobacterium abundance and butyrate in a dose dependent manner. The investigators will test 1, 5, or 10 gm 2'-FL compared to 2 gm dextrose placebo as a daily dietary supplement in pediatric and young adult IBD participants in stable remission receiving inflixi... Read More
Gender:
ALL
Ages:
Between 11 years and 25 years
Trial Updated:
06/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Register for Updates
Beat Childhood Cancer Specimen Banking and Data Registry
NCT04715178
Recruiting
This is an observational data registry study of pediatric cancer patients at participating Beat Childhood Cancer Consortium sites involving specimen banking and data collection.
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Pediatric Cancer, Survivorship
Register for Updates